American Association for Cancer Research
Browse
00085472can130615-sup-fig5.pdf (38.93 kB)

Supplementary Figure 5 from RNAi-Mediated Silencing of Myc Transcription Inhibits Stem-like Cell Maintenance and Tumorigenicity in Prostate Cancer

Download (38.93 kB)
journal contribution
posted on 2023-03-30, 22:09 authored by Gianluca Civenni, Anastasia Malek, Domenico Albino, Ramon Garcia-Escudero, Sara Napoli, Stefano Di Marco, Sandra Pinton, Manuela Sarti, Giuseppina M. Carbone, Carlo V. Catapano

PDF file - 38K, PC3 cells cultured in sphere forming conditions (bulk) and sorted subpopulations (CD44+/CD24- and CD44+/CD24+) were transfected with Myc13-Cy3 siRNA and the intracellular level of Cy3-labeled siRNA was determined after 4 h by flow cytometry.

History

ARTICLE ABSTRACT

Several studies link disease progression, recurrence, and treatment failures to the cancer stem-like cell (CSC) subpopulation within the heterogeneous tumor cell population. Myc is a transcription factor having a central function in stem cell biology and in human cancers. Hence, Myc represents an attractive target to develop CSC-specific therapies. Recent findings suggest that Myc transcription can be silenced using an RNA interference (RNAi)–based strategy that targets noncoding promoter-associated RNA (paRNA) overlapping the transcription start site. In this study, we investigated the effects of silencing Myc transcription on prostate CSC in cell culture and xenograft models of human prostate cancer. Treatment with an effective promoter-targeting siRNA reduced the fraction of CSCs, leading to reduced self-renewal, tumor-initiating, and metastatic capability. Combined analysis of stem-like cells and senescence markers indicated that Myc silencing triggered a phenotypic shift and senescence in the CSC subpopulation. Notably, systemic delivery of the promoter-targeting siRNA in the xenograft model produced a striking suppression in the development of prostate tumors. Our results support a pivotal role for Myc in CSC maintenance and show that Myc targeting via RNAi-based transcriptional silencing can trigger CSC senescence and loss of their tumor-initiating capability. More generally, our findings demonstrate the efficacy of RNAi-based transcriptional strategies and the potential to target regulatory noncoding paRNAs for therapeutic applications. Cancer Res; 73(22); 6816–27. ©2013 AACR.

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC